 Available clinical trial data suggest that a new method of combating HIV-1 may be found in CCR5 antagonists.Studies into vicriviroc are ongoing, and another CCR5 antagonist, maraviroc, is currently on the market.However, concerns have arisen regarding the use of CCR5 antagonists as anti-HIV treatments because such drugs may facilitate the emergence of resistant strains of HIV-1.